Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IL28RA polymorphism (rs10903035) is associated with insulin resistance in HIV/HCV-coinfected patients.
Jiménez-Sousa MA, Berenguer J, Fernández-Rodríguez A, Micheloud D, Guzmán-Fulgencio M, Miralles P, Pineda-Tenor D, García-Álvarez M, López JC, Aldámiz-Echevarria T, Carrero A, Resino S. Jiménez-Sousa MA, et al. Among authors: carrero a. J Viral Hepat. 2014 Mar;21(3):189-97. doi: 10.1111/jvh.12130. Epub 2013 Jul 17. J Viral Hepat. 2014. PMID: 24438680
Association between IL7RA polymorphisms and the successful therapy against HCV in HIV/HCV-coinfected patients.
Guzmán-Fulgencio M, Berenguer J, Pineda-Tenor D, Jiménez-Sousa MA, García-Álvarez M, Aldámiz-Echevarria T, Carrero A, Diez C, Tejerina F, Vázquez S, Briz V, Resino S. Guzmán-Fulgencio M, et al. Among authors: carrero a. Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):385-93. doi: 10.1007/s10096-014-2245-1. Epub 2014 Sep 19. Eur J Clin Microbiol Infect Dis. 2015. PMID: 25236396
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Santos J, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GESIDA 7011 Study Group. Perez-Molina JA, et al. Lancet Infect Dis. 2015 Jul;15(7):775-84. doi: 10.1016/S1473-3099(15)00097-3. Epub 2015 Jun 7. Lancet Infect Dis. 2015. PMID: 26062881 Clinical Trial.
Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study).
Perez-Molina JA, Rubio R, Rivero A, Pasquau J, Suárez-Lozano I, Riera M, Estébanez M, Palacios R, Sanz-Moreno J, Troya J, Mariño A, Antela A, Navarro J, Esteban H, Moreno S; GeSIDA 7011 Study Group. Perez-Molina JA, et al. J Antimicrob Chemother. 2017 Jan;72(1):246-253. doi: 10.1093/jac/dkw379. Epub 2016 Sep 13. J Antimicrob Chemother. 2017. PMID: 27629070 Free article. Clinical Trial.
Effects of Hepatitis C Virus (HCV) Eradication on Bone Mineral Density in Human Immunodeficiency Virus/HCV-Coinfected Patients.
Carrero A, Berenguer J, Hontañón V, Guardiola JM, Navarro J, von Wichmann MA, Téllez MJ, Quereda C, Santos I, Sanz J, Galindo MJ, Hernández-Quero J, Jiménez-Sousa MA, Pérez-Latorre L, Bellón JM, Resino S, Esteban H, Martínez E, González-García J; Grupo de Estudio del Sida (GESIDA) 3603B Study Group. Carrero A, et al. Clin Infect Dis. 2021 Oct 5;73(7):e2026-e2033. doi: 10.1093/cid/ciaa1396. Clin Infect Dis. 2021. PMID: 32930720
HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients.
Brochado Ó, Martínez I, Berenguer J, Medrano L, González-García J, Jiménez-Sousa MÁ, Carrero A, Hontañón V, Navarro J, Guardiola JM, Fernández-Rodríguez A, Resino S; GESIDA Study Group. Brochado Ó, et al. Among authors: carrero a. J Biomed Sci. 2021 Mar 30;28(1):23. doi: 10.1186/s12929-021-00718-6. J Biomed Sci. 2021. PMID: 33785040 Free PMC article.
HIV/HBV coinfection: temporal trends and patient characteristics, Spain, 2002 to 2018.
Pérez-Latorre L, Berenguer J, Micán R, Montero M, Cifuentes C, Puig T, Sanz J, Ferrero OL, De La Fuente B, Rodríguez C, Reus S, Hernández-Quero J, Gaspar G, Pérez-Martínez L, García C, Force L, Veloso S, De Miguel M, Jarrín I, González-García J; GeSIDA 8514 Study Group. Pérez-Latorre L, et al. Euro Surveill. 2021 Jun;26(25):2000236. doi: 10.2807/1560-7917.ES.2021.26.25.2000236. Euro Surveill. 2021. PMID: 34169818 Free PMC article.
Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.
Martín-Escolano R, Virseda-Berdices A, Berenguer J, González-García J, Brochado-Kith O, Fernández-Rodríguez A, Díez C, Hontañon V; Marathon Study Group; Resino S, Jiménez-Sousa MÁ. Martín-Escolano R, et al. Front Pharmacol. 2024 Oct 28;15:1341612. doi: 10.3389/fphar.2024.1341612. eCollection 2024. Front Pharmacol. 2024. PMID: 39530457 Free PMC article.
66 results